CALGARY, April 27, 2017 /PRNewswire/ - Oncolytics
Biotech® Inc. (Oncolytics or the Company) (TSX:ONC)
(OTCQX:ONCYF) announced today that its 2017 Annual Meeting of
Shareholders will be held on Thursday, May
4th, 2017 at 4:00 pm
ET (2:00 pm MT) at the Toronto
Region Board of Trade located at First Canadian Place, Suite 350,
77 Adelaide Street West, Toronto,
Ontario.
Following the business portion of the meeting, Dr. Matt Coffey, President and CEO of Oncolytics,
will discuss recent progress in the development of
REOLYSIN®, including recent randomized phase 2
metastatic breast cancer results as well as the detailed clinical
development plan and specific initial registration pathway for
REOLYSIN.
A live audio webcast of Dr. Coffey's presentation will begin at
approximately 4:15 pm ET
(2:15 pm MT) and be available at
http://event.on24.com/r.htm?e=1415093&s=1&k=1D9EC98BC2D829CD19D1A85F7769DEAC
and on the company's website
at http://www.oncolyticsbiotech.com/investor-centre/presentations.
It is recommended that listeners log on 10 minutes in advance of a
live session to register and download any necessary software. An
audio replay will be accessible approximately two hours following
the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an immuno-oncology
viral-agent, as a potential treatment for a variety of tumor types.
The compound induces selective tumor lysis and promotes an inflamed
tumor phenotype through innate and adaptive immune responses to
treat a variety of cancers. Oncolytics' clinical development
program emphasizes three pillars: chemotherapy combinations to
trigger selective tumor lysis; immuno-therapy combinations to
produce adaptive immune responses; and immune modulator (IMiD)
combinations to facilitate innate immune responses.
Oncolytics is currently planning its first registration study in
breast cancer, as well as studies in combination with checkpoint
inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics,
please visit: www.oncolyticsbiotech.com.
This press release and the presentation related thereto
contain forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's belief as to
the potential of REOLYSIN® as a cancer therapeutic; the
Company's expectations as to the success of its research and
development programs in 2017 and beyond, the Company's planned
operations, the value of the additional patents and intellectual
property; the Company's expectations related to the applications of
the patented technology; the Company's expectations as to adequacy
of its existing capital resources; the design, timing, success of
planned clinical trial programs; and other statements related to
anticipated developments in the Company's business and technologies
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN
as a cancer treatment, the success and timely completion of
clinical studies and trials, the Company's ability to successfully
commercialize REOLYSIN, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.